High-fat Challenge Induced Trained Innate Immunity (SHAKE Study)

High-fat Challenge Induced Trained Innate Immunity

The goal of this randomized controlled cross-over trial is to investigate whether a single high-fat challenge can induce trained innate immunity in healthy volunteers. The main question it aims to answer is: Can a single high-fat challenge induce a persistent pro-inflammatory and pro-atherogenic monocyte phenotype, as detected by an augmented cytokine production capacity? To study this, participants will receive an oral high-fat and reference shake in a cross-over design and blood will be drawn before and at 1, 2, 4, 6, 24, and 72 hours after the shakes.

Study Overview

• Status: Completed
• Conditions: Cardiovascular Diseases
• Intervention / Treatment: Dietary supplement: High-fat shake; Dietary supplement: Reference shake

Detailed Description

Rationale: Atherosclerosis is characterized by a persistent inflammation of the arterial wall.

Monocyte-derived macrophages are the most abundant immune cells in atherosclerotic plaques. It has recently been shown that not only immune cells of the adaptive immune system, but innate immune cells as well are able to adopt a long-term pro-inflammatory phenotype upon stimulation. This nonspecific memory of innate immune cells is mediated by epigenetic and metabolic reprogramming and is termed "trained innate immunity." Previous findings from our lab have shown that not only bacterial components such as LPS, but also pro-atherogenic particles such as oxidized LDL can induce trained immunity in monocytes. Interestingly, this memory-effect of trained immunity indicates that even temporary triggers could induce the persistent inflammation in atherosclerosis.

Triglyceride-rich lipoproteins (TRL) have been identified as an important independent risk factor for atherosclerosis. Moreover, elevated plasma levels of these lipoproteins are associated with increased pro-inflammatory markers. TRLs, however, are characterized by alternating plasma levels, with brief elevations following (fat containing) meals. Notably, a high-fat meal not only contributes to the transient increase of TRL plasma levels, but also induces a brief elevation in LPS levels by briefly increasing the permeability of the gut.

We now aim to investigate whether a single high-fat meal can induce trained innate immunity, since this concept might explain how brief postprandial effects can translate into a long-term pro-inflammatory and pro-atherogenic monocyte phenotype.

Objective: The primary objective is to determine whether a high-fat meal can induce a persistent pro-inflammatory monocyte phenotype, characterized by an increased cytokine production capacity upon ex vivo stimulation. Secondary objectives are metabolic and epigenetic reprogramming of monocytes at these time points as well as the capacity of serum, isolated before and 1-6h after an oral fat load, to induce an increased cytokine production in healthy human monocytes.

Study design: Randomized cross-over high-fat challenge intervention study.

Study population: Healthy human volunteers, aged between 18 and 40 years.

Intervention: A single high-fat challenge (milkshake containing 95g of fat) and 'control' shake (comparable to an average breakfast).

Main study parameters/endpoints: Blood will be drawn at t=0h (before) and at t=1h, t=2h, t=4h, t=6h, t=24 and t=72h after an oral fat load and at the same time points after a 'control' shake. The primary endpoint is the monocyte TNFα production upon ex vivo stimulation with LPS at the 72h time point. Additional secondary endpoints are the production of other cytokines and chemokines upon ex vivo stimulation at t=0h, t=4h, t=24h and t=72h, the monocytes' inflammatory phenotype as assessed by flowcytometry analysis and serum induced persistent cytokine production capacity.

• Study Type: Interventional
• Enrollment (Actual): 16
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Netherlands
  • Gelderland
    • Nijmegen, Gelderland, Netherlands, 6525 GA
      • Radboudumc

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 40 years (Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• LDL cholesterol < 3.5 mmol/l, fasting triglycerides < 2 mmol/l
• No previous cardiovascular events

Exclusion Criteria:

• Smoking within the year before study entry
• Diagnosed with any long-term medical condition that can interfere with the study (i.e.

gallbladder disease, renal failure, cardiovascular disease, diabetes, rheumatoid arthritis etc.)

• Medication (with the exception of oral contraceptives) or supplement use (i.e. omega3)
• BMI < 18 or > 27 kg/m2
• Previous vaccination within 3 months prior to study entry
• Current infection or clinically significant infections within 1 month before study entry (defined as fever > 38.5°C)
• Allergic to cow milk/dairy products
• Pregnancy/lactation
• Abuse of drugs or alcohol
• Vegetarian diet

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Basic Science
• Allocation: Randomized
• Interventional Model: Crossover Assignment
• Masking: Single

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: High-fat shake	Dietary supplement: High-fat shake; The high-fat shake consisted of 53% (w/v) fresh cream, 3% (w/v) sugar and 44% (w/v) water
Active Comparator: Reference shake	Dietary supplement: Reference shake; The reference shake consisted of 43% (w/v) full cream milk, 48% (w/v) full cream yoghurt, 4% (w/v) lemonade, 4% (w/v) fantomalt (Nutricia B.V., the Netherlands) and 1% (w/v) wheat fiber

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Monocyte TNFα production upon ex vivo stimulation with LPS	72 hours

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
The monocyte production of TNFa, IL-6, IL-1beta, IL-10 upon ex vivo stimulation with LPS, Pam3Cys or Candida Albicans.		0 hour, 4 hours, 24 hours and 72 hours
The monocyte's inflammatory phenotype as assessed by flowcytometry analysis (i.e. membrane expression of markers including but not limited to CD14, CD16, CD11b, CCR2)		0 hour, 4 hours, 24 hours and 72 hours
Postprandial serum-induced TNFa and IL-6 production of healthy human monocytes upon stimulation with LPS or Pam3Cys 6 days later.	Serum isolated before and after consumption of a high-fat meal is used in in vitro studies. In these studies isolated monocytes of healthy human donors are exposed to pooled fasting (t=0h) or fed serum (t=2h, 4h, or 6h) obtained from the study participants. The TNFa and IL-6 production of these cells is measured after stimulation with LPS and Pam3Cys 6 days later. Subsequently, it is studied whether a possible increase in TNFa or IL-6 production can be prevented by co-incubation with pharmacological inhibitors (e.g. TLR4 antagonists/inhibitors)	0 hour, 2 hours, 4 hours , 6 hours
Plasma triglyceride, glucose, free fatty acid and insulin concentrations	The baseline (t=0h) and postprandial concentrations (at t=1h, 2h, 4h and 6h) of circulating triglycerides, glucose, free fatty acids and insulin are measured in the study participants after consumption of both the high-fat and control shake.	0 hour, 1 hour, 2 hours, 4 hours , 6 hours

Collaborators and Investigators

• Sponsor: Radboud University Medical Center
• Investigators: Principal Investigator: Niels Riksen, MD, PhD, Vascular Internal Medicine, Radboudumc

Study record dates

Study Major Dates

• Study Start (Actual): May 6, 2019
• Primary Completion (Actual): January 9, 2020
• Study Completion (Actual): October 15, 2021

Study Registration Dates

• First Submitted: December 16, 2022
• First Submitted That Met QC Criteria: December 27, 2022
• First Posted (Actual): January 12, 2023

Study Record Updates

• Last Update Posted (Actual): January 12, 2023
• Last Update Submitted That Met QC Criteria: December 27, 2022
• Last Verified: December 1, 2022

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Cardiovascular Diseases
• Other Study ID Numbers: 107808; NTR7612 (Registry Identifier: Netherlands Trial Register)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: Undecided

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No